BPTH - Bio-Path Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
15.02
-2.15 (-12.52%)
As of 3:04PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close17.17
Open15.63
Bid14.89 x 1100
Ask14.89 x 1100
Day's Range14.50 - 16.17
52 Week Range1.61 - 73.52
Volume567,387
Avg. Volume213,270
Market Cap42.527M
Beta (3Y Monthly)3.53
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire2 months ago

    Bio-Path Holdings Reports First Quarter 2019 Financial Results

    Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2019 and provided an update on recent corporate developments. “During the first quarter, we continued to execute on our strategic initiatives to build our DNAbilize® technology and advance our clinical development programs.

  • ACCESSWIRE2 months ago

    Bio-Path Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 16, 2019 / Bio-Path Holdings, Inc. (NASDAQ: BPTH ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 16, 2019 at 8:30 AM Eastern ...

  • GlobeNewswire2 months ago

    Bio-Path Holdings to Announce First Quarter 2019 Financial Results on May 16, 2019

    Bio-Path Holdings, Inc., (BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 16, 2019 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2019 and to provide a business overview. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion.

  • ACCESSWIRE3 months ago

    Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)

    BELLAIRE, TX / ACCESSWIRE / April 29, 2019 / Bio-Path Holdings, Inc. (NASDAQ: BPTH). The full report can be accessed by clicking on the following link: http://stonegateinc.com/reports/BPTH%20Update%20April%202019%20Final%20v4.pdf ...

  • GlobeNewswire3 months ago

    Bio-Path Holdings Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2019

    Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced that data from pre-clinical studies supporting the potential of BP1003, a novel liposome-incorporated STAT3 oligodeoxynucleotide inhibitor, for the treatment of pancreatic cancer, non-small cell lung cancer (NSCLC) and acute myelogenous leukemia (AML) were presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2019 today in Atlanta, GA. The poster, entitled “BP1003, a Novel Liposome-Incorporated STAT3 Antisense Oligodeoxynucleotide Inhibitor,” was presented by Ana Tari Ashizawa, Ph.D., Vice President of Research and Development at Bio-Path.

  • GlobeNewswire4 months ago

    Bio-Path Holdings Reports Full Year 2018 Financial Results

    Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the full year ended December 31, 2018 and provided an update on recent corporate developments. “Throughout 2018, we made great progress in pursuit of our mission of bringing innovative new RNAi nanoparticle therapeutics to cancer patients with high unmet medical need,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.  “This progress was highlighted by the recent updated interim analysis of our Phase 2 trial of prexigebersen in acute myeloid leukemia (AML). Of the 17 evaluable patients, 65% had a response, including 29% who achieved a complete response, one of which achieved a morphologic leukemia free state.

  • GlobeNewswire4 months ago

    Bio-Path Holdings to Announce Fourth Quarter and Full Year 2018 Financial Results on March 20, 2019

    HOUSTON, March 15, 2019 -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to.

  • Business Wire4 months ago

    Bio-Path Holdings, Inc. Announces Closing of $18.5 Million Registered Direct Offering of Common Stock

    Bio-Path Holdings, Inc. (BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing of its previously announced offering. In a registered direct offering, Bio-Path issued and sold 712,910 shares of its common stock for a price of $25.95 per share, for aggregate gross proceeds of approximately $18.5 million. Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes.

  • GlobeNewswire4 months ago

    Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock

    Bio-Path Holdings, Inc., (BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into definitive agreements with several healthcare focused institutional investors for the issuance and sale in a registered direct offering of 712,910 shares of its common stock, at a purchase price of $25.95 per share, for aggregate gross proceeds of approximately $18.5 million. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes.

  • ACCESSWIRE4 months ago

    The Device Market That Drove One Company From $2.50 to $65 Has a New Entrant

    The move to get patients out of doctors offices and hospitals quickly using virtual care and remote monitoring is underway. Technology is enabling the switch, and few sub-sectors have benefited more than remote cardiac care. Companies like Biotelemetry (BEAT) have grown by leaps and bounds in the last few years as their proprietary remote cardiac monitoring devices have gained traction.

  • ACCESSWIRE4 months ago

    Bio-Path Holdings Updates Clinical Trial Data and it Sounds Promising

    NEW YORK, NY / ACCESSWIRE / March 6, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Bio-Path Holdings, Inc. (BPTH), a company that develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Bio-Path announced a clinical update to the previously reported interim analysis from the Phase 2 trial of prexigebersen (BP1001) for the treatment of acute myeloid leukemia (AML) and provides its plans for the compound's clinical development moving forward toward registration.

  • ACCESSWIRE4 months ago

    Under the Radar Cannabis Stock-THC Therapeutics, Inc.

    HENDERSON, NV / ACCESSWIRE / March 6, 2019 / Cannabis research firm, ArcView, sees North American legal pot sales reaching $22 billion by 2021 and $57 billion worldwide by 2027. So, it's little surprise ...

  • GlobeNewswire4 months ago

    Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

    Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces a clinical update to the previously reported interim analysis from the Phase 2 trial of prexigebersen (BP1001) for the treatment of acute myeloid leukemia (AML) and provides its plans for the compound’s clinical development moving forward toward registration. The open-label Phase 2 study in Stage 1 evaluated the efficacy and safety of prexigebersen in conjunction with low dose cytarabine (LDAC), a therapeutic regimen well-established in treatment of AML patients who cannot or elect not to be treated with more intensive chemotherapy.  The primary objective of the study is to determine whether the combination of prexigebersen and LDAC provides greater efficacy than would be expected with LDAC alone in a de novo patient population. Subsequently, Stage 2 of the study added a second cohort that is evaluating the efficacy and safety of prexigebersen in conjunction with Decitabine in addition to the cohort evaluating prexigebersen in conjunction with LDAC.

  • GlobeNewswire5 months ago

    Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting

    HOUSTON, Feb. 28, 2019 -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to.

  • GlobeNewswire6 months ago

    Bio-Path Holdings, Inc. Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market

    Bio-Path currently intends to use the net proceeds from the offerings for working capital and general corporate purposes. The shares of common stock offered in the registered direct offering (but not the warrants or the shares of common stock underlying the warrants) were offered and sold by Bio-Path pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-215205), including a base prospectus, previously filed with and declared effective by the Securities and Exchange Commission (SEC) on January 9, 2017.  The offering of the shares of common stock was made only by means of a prospectus supplement that forms a part of the registration statement.

  • GlobeNewswire6 months ago

    Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market

    The warrants will have an exercise price of $2.65 per share and exercise period commencing immediately upon issuance and a term of five and one-half (5.5) years. Bio-Path currently intends to use the net proceeds from the offerings for working capital and general corporate purposes.

  • GlobeNewswire6 months ago

    Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

    As a result of the reverse stock split, every 20 shares of common stock issued and outstanding were consolidated into one issued and outstanding share.  The reverse stock split reduced the Company’s issued and outstanding shares of common stock from approximately 22.2 million to approximately 1.1 million. In addition, proportionate adjustments will be made to the exercise prices of the Company's outstanding stock options and warrants and to the number of shares issued and issuable under the Company's existing stock incentive plans.

  • GlobeNewswire6 months ago

    Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common Stock

    Bio-Path Holdings, Inc., (BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing and funding of its previously announced underwritten public offering of 8,592,308 shares of its common stock at a price to the public of $0.13 per share. Bio-Path currently intends to use the net proceeds from the offering for working capital and general corporate purposes. A shelf registration statement on Form S-3 (Registration No. 333-215205) relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (“SEC”) and was declared effective on January 9, 2017.

  • GlobeNewswire6 months ago

    Bio-Path Holdings, Inc. Announces Pricing of Public Offering of Common Stock

    Bio-Path Holdings, Inc., (BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the pricing of an underwritten public offering of 8,592,308 shares of its common stock at a price to the public of $0.13 per share. Bio-Path expects to receive aggregate gross proceeds of approximately $1.1 million from the offering. The offering is expected to close on or about January 17, 2019, subject to the satisfaction of customary closing conditions.

  • GlobeNewswire6 months ago

    Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

    Bio-Path Holdings, Inc., (BPTH) (Bio-Path),  a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

  • GlobeNewswire7 months ago

    Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook

    Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides an update from several clinical development programs and a 2019 business overview. “Over the last year, we made solid progress across our growing development pipeline, highlighted by positive interim data from our Phase 2 study of prexigebersen in de novo acute myeloid leukemia (AML) patients,” stated Peter H. Nielsen, chief executive officer of Bio-Path Holdings.

  • GlobeNewswire7 months ago

    Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting

    Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that previously announced interim data from the Company’s Phase 2 study evaluating prexigebersen as a treatment for acute myeloid leukemia (AML) were presented in a poster at the 2018 American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 1-4, 2018 in San Diego, CA. Prexigebersen was safely administered to patients with untreated AML, who were considered unsuitable for standard chemotherapy.

  • GlobeNewswire8 months ago

    Bio-Path Holdings Reports Third Quarter 2018 Financial Results

    Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2018 and provided an update on recent corporate developments. “Throughout the third quarter, we continued to make meaningful progress advancing and expanding our robust clinical development pipeline of RNAi nanoparticle drugs to bring innovative new treatments to cancer patients with high unmet medical need,” stated Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.  “Most recently, we were delighted to report that interim data from our ongoing Phase 2 clinical trial of prexigebersen for the treatment of acute myeloid leukemia (AML) were accepted for poster presentation at the upcoming American Society of Hematology Annual Meeting (ASH) taking place in early December 2018.